5 unknown, 3 completed, 1 recruiting, 1 terminated. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Unknown 3 |
| Phase 1 | 1 | Terminated 1 |
Follow EGFR T790M: new trials by email Literature Review of EGFR T790M trials Research Report on EGFR T790M
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation Non Small Cell Lung Cancer, EGFR T790M | Recruiting | LifeOS Genomics Corporation | 300 | 2024-09-06 | 2024-11-18 | |
| Lazertinib 160mg in EGFR T790M NSCLC Lazertinib - Lung Cancer Stage IV, EGFR T790M | Phase 2 | Unknown | Samsung Medical Center | 117 | 2023-02-01 | 2023-01-27 |
| Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer Lazertinib - Metastatic Lung Non-Small Cell Carcinoma, EGFR T790M | Unknown | Samsung Medical Center | 900 | 2022-07-31 | 2022-05-19 | |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
| Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer Almonertinib, Pemetrexed, Carboplatin - Lung Cancer, Non-small Cell, EGFR T790M | Phase 2 | Unknown | Fudan University | 226 | 2020-10-09 | 2020-10-19 |
| Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC Osimertinib - EGFR T790M, Osimertinib | Phase 2 | Unknown | Peking Union Medical College | 80 | 2020-09-15 | 2022-07-26 |
| Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC) Aspirin, Osimertinib - Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Unknown | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 100 | 2020-08-01 | 2020-07-23 | |
| Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS) Osimertinib - NSCLC, EGFR T790M | Phase 2 | Completed | University Hospital, Essen | 16 | 2019-06-03 | 2024-05-09 |
| D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer D-0316 - Solid Tumor, NSCLC | Phase 2 | Completed | InventisBio Co., Ltd | 290 | 2019-02-28 | 2024-04-09 |
| Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC Osimertinib, Aspirin - Non-Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV | Phase 2 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 115 | 2018-01-01 | 2025-02-27 |
Carcinoma, Non-Small-Cell Lung (7) · Lung Neoplasms (4) · Adenocarcinoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Nerve Tissue (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Lung Diseases (7) · Neoplasms (7) · Neoplasms by Site (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Bronchial Neoplasms (6) · Carcinoma, Bronchogenic (6) · Lung Neoplasms (4) · Bronchial Diseases (1) · Neoplasms, Glandular and Epithelial (1)
osimertinib (5) · Aspirin (2) · Carboplatin (2) · Pemetrexed (2) · lazertinib (2) · Paclitaxel (1) · aumolertinib (1)
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (2) · Samsung Medical Center (2) · Blueprint Medicines Corporation (1) · Fudan University (1) · InventisBio Co., Ltd (1) · LifeOS Genomics Corporation (1) · Peking Union Medical College (1) · University Hospital, Essen (1)
China (4) · South Korea (3) · Taiwan (2) · Canada (1) · France (1) · Germany (1) · Japan (1) · Netherlands (1) · Singapore (1) · Spain (1) · United Kingdom (1) · United States (1)
Jin Seok Ahn, MD, PhD (1) · Junling Li, Professor (1) · Shun Lu (1) · Sung-Liang Yu, PhD (1)
PMID 27959700, PMID 35724798, PMID 38526910, PMID 38575188, PMID 39089004